Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Sanne J. de Haart, Lisa Holthof, Willy A. Noort, Monique C. Minnema, Maarten E. Emmelot, Tineke Aarts-Riemens, Parul Doshi, Kate Sasser, Huipin Yuan, Joost de Bruijn, Anton C. M. Martens, Niels W. C. J. van de Donk, Henk M. Lokhorst, Richard W. J. Groen, Tuna Mutis

Research output: Contribution to journalArticleAcademicpeer-review

26 Citations (Scopus)
Original languageEnglish
Pages (from-to)E339-E343
Issue number8
Publication statusPublished - Aug 2016


  • abrogation
  • bone marrow stromal cell
  • cell lysis
  • deratumumab
  • multiple myeloma
  • sepantronium bromide

Cite this